Pipeline
Armed with our powerful technologies, we are developing a pipeline of low sugar universal vaccines and glyco-optimized antibody products. Our lead program, a low sugar protein subunit vaccine against COVID, is now well underway in a Phase I trial in the US. We are confident that it will demonstrate our technology to be a safe and effective way to induce broadly protective immunity in humans. We are now looking to expand this vaccine platform to include mRNA vaccine programs against flu, either by itself or in combination with COVID, with an HIV program to follow. Our glycoengineered biobetter platform can be widely applied to many protein biologics, and we are starting with three well known antibody drugs as a proof of concept, selected based on their market potential, mechanisms of action, and patent statuses.
